Outcome of intravenous immunoglobulin-transmitted hepatitis C virus infection in primary immunodeficiency
(c)2001 Elsevier Science.
| Veröffentlicht in: | Clinical immunology (Orlando, Fla.). - 1999. - 101(2001), 3 vom: 07. Dez., Seite 284-8 |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | , , |
| Format: | Aufsatz |
| Sprache: | English |
| Veröffentlicht: |
2001
|
| Zugriff auf das übergeordnete Werk: | Clinical immunology (Orlando, Fla.) |
| Schlagworte: | Journal Article Antiviral Agents Immunoglobulins, Intravenous Interferon-alpha Ribavirin 49717AWG6K |
| Zusammenfassung: | (c)2001 Elsevier Science. Physicians in the United States who treat patients with primary immunodeficiency were contacted to identify subjects who had been infected with hepatitis C due to exposure to contaminated intravenous immunoglobulin (IVIg) in 1993-1994. From this survey we gathered information on 58 PCR-positive hepatitis C-infected patients; 37 had CVID, 9 had XLA, 5 were IgG subclass deficient, 4 were antibody deficient with normal immunoglobulin levels, 2 had SCID after BMT, and 1 had B cell linker deficiency. Of the 58 subjects, 30 had been treated with IFN-alpha in combination with ribavirin in 5 cases, and 26 other subjects were not treated. Of those who were treated, 11 (37%) resolved the infection and became PCR-negative; of the 26 who were not treated, 5 (19%) have resolved the infection, outcomes not significantly different. Patients 20 years of age or younger had a significantly better outcome compared to those older than age 20 (P = 0.02). Five subjects of the 58 have had a liver transplantation, a sixth has had two transplants, and 10 (17%) of the group have died. This survey demonstrates the heterogeneity of the clinical outcome in subjects with primary immunodeficiency who contracted hepatitis C due to viral contamination of IVIg |
|---|---|
| Beschreibung: | Date Completed 10.01.2002 Date Revised 19.11.2015 published: Print Citation Status MEDLINE |
| ISSN: | 1521-7035 |